Yunnan Baiyao Group Co Ltd (000538) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Yunnan Baiyao Group Co.,Ltd engages in the sale of pharmaceuticals, medicinal materials, health and daily chemical products in China.

Total Revenue Chart for Yunnan Baiyao Group Co Ltd

Yunnan Baiyao Group Co Ltd (000538) revenue for FY2025 was CNY 41.2B, a 2.9% change from FY2024. Yunnan Baiyao Group Co Ltd's revenue grew from CNY 37.3M in 1991 to CNY 41.2B in 2025 (110437.3% over 34 years). Earnings per share grew from CNY 0.05 in 2000 to CNY 1.56 in 2021 (2867.9%). Revenue compound annual growth rate: 5-year CAGR of 4.7%, 10-year CAGR of 7.1%, 20-year CAGR of 15.2%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (CNY)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
¥91.03B
Implied Share Price
¥51.02
Enterprise Value
¥76.59B
Revenue (TTM)
¥41.81B
EBITDA
¥5.09B
Profit Margin
12.49%
Trailing P/E
17.47
Forward P/E
21.37
Price/Book (MRQ)
2.21
Price/Sales (TTM)
2.18
EV/EBITDA
11.68
EV/Revenue
1.82
Dividend Yield
3.12%
Book Value
¥22.96
Free Cash Flow (FY2025)
¥4.12B
Free Cash Flow Yield
4.53%

Snapshot as of 5th September 2026 — not point-in-time controlled, may lag the live market by a few days.